Pfizer Launches Newly Combined CMO

April 20, 2016
BioPharm International Editors

Pfizer announced the launch of Pfizer CentreOne, a CMO formed by the combination of Pfizer CentreSource and Hospira One 2 One.

Pfizer’s newly combined global CMO, Pfizer CentreOne, launched on April 20, 2016. The CMO will focus specifically on API synthesis and sterile injectables fill-finish, Pfizer said in a press announcement.

Pfizer CentreOne was formed by the combination of Pfizer CentreSource and Hospira One 2 One. The formation comes after Pfizer acquired One 2 One in September 2015. The newly formed CMO plans to combine Pfizer’s knowledge of specialty APIs with One 2 One’s work with sterile injectables.

Pfizer CentreOne’s core offerings will include:

  • Small-molecule steroid and hormone intermediates and APIs

  • Custom small-molecule API synthesis

  • Sterile injectables fill-finish.

“As a combined organization, we’ve brought together the best of our manufacturing capabilities to provide a wider array of services and technologies to our biopharmaceutical partners,” said Peter Stevenson, vice-president and general manager of Pfizer CentreOne, in a press announcement. “Although Pfizer CentreOne is a new name, we’ve been providing contract manufacturing services for more than 40 years and are committed to further growing our business.”

Source: Pfizer